Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug
- 1 August 2002
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 110 (2), 277-284
- https://doi.org/10.1067/mai.2002.126500
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled studyBritish Journal of Dermatology, 2001
- Managing pediatric atopic dermatitis.Clinical Pediatrics, 2000
- A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacologyBritish Journal of Dermatology, 1999
- Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner.Archives of Dermatological Research, 1998
- A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases:in vivopharmacologyBritish Journal of Dermatology, 1997
- A topic dermatitis the skin manifestation of a topicClinical and Experimental Allergy, 1995
- Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointmentThe Lancet, 1995
- The prevalence of childhood atopic eczema in a general populationJournal of the American Academy of Dermatology, 1994
- Efficacy Versus Systemic Effects of Six Topical Steroids in the Treatment of Atopic Dermatitis of ChildhoodPediatric Dermatology, 1984
- Dwarfism Following Long-term Topical Corticosteroid TherapyPublished by American Medical Association (AMA) ,1980